Seagen and Zai Lab ink part­ner­ship on Tiv­dak ex­pan­sion in­to Chi­na and sur­round­ing ar­eas; NC biotech snaps up seed fund­ing

Zai Lab has signed on to com­mer­cial­ize Seagen and Gen­mab’s Tiv­dak — an ADC for re­cur­rent or metasta­t­ic cer­vi­cal can­cer in pa­tients in which chemother­a­py isn’t work­ing — in main­land Chi­na, Hong Kong, Macau and Tai­wan.

Seagen will get $30 mil­lion up­front, along with down­stream mile­stone pay­ments and tiered roy­al­ties. But the com­pa­ny will be split­ting all earn­ings from the Zai Lab agree­ment 50:50 with Gen­mab.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.